Allergan Reports FDA’s Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension

 Allergan Reports FDA’s Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension

Allergan Reports FDA’s Acceptance of NDA for Bimatoprost Sustained-Release to Treat Glaucoma or Ocular Hypertension

Shots:

  • The NDA submission is based on P-III ARTEMIS studies results assessing Bimatoprost SR vs timolol in 1122 patients with open-angle glaucoma or ocular hypertension for 12wks.
  • The P-III ARTEMIS studies results demonstrated 30% reduction in intraocular pressure (IOP) and more than 80% remained treatment free with no maintenance treatment for at least 12 mos. following 3 treatments with Bimatoprost SR and is well tolerated
  •  Bimatoprost (marketed as Lumigan 0.01%) available as an eyedrop indicated to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Click here to read full press release/ article | Ref: Allergan | Image: Market watch

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post